meta|evidence oncology

Living systematic review and meta-analysis

refractory classic Hodgkin lymphoma (R/R cHL)
R/R cHL - second line or more (L2) 1
colorectal cancer (CRC)

chemotherapy
non platinum-based chemotherapy
nucleoside analogues (pyrimidine/purine)
capecitabine
Standard of Care (SoC)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus bevacizumab
atezolizumab plus cometinib
atezolizumab plus FOLFOXIRI plus bevacizumab
atezolizumab plus SoC
avelumab based treatment
avelumab alone
durvalumab based treatment
nivolumab based treatment
nivolumab plus SoC
pembrolizumab based treatment
pembrolizumab alone
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab

versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs nucleoside analogues (pyrimidine/purine)
vs capecitabine
vs Standard of Care (SoC)
vs non active control
vs BSC
vs VEGF(R) inhibitor
vs bevacizumab based treatment
vs Bevacizumab plus FOLFOXIRI
vs placebo plus bevacizumab
vs regorafenib

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

Study		Exclusion reasons	Remarks	Reference(s)
Empty list - no studies excluded

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -